Informative Videos

Informative Media

Dr. Anghel interview on HealthLink On Air podcast.

Dr. Ahmed interview on HealthLink On Air podcast.

Helpful Links

watchman logo

This new procedure is the only FDA-approved implant proven to reduce stroke risk in people with atrial fibrillation not caused by a heart valve problem (also referred to as non-valvular AFib).

A Trusted Partner Providing Reliable Information On Medicines

At St. Jude Medical, we build upon a legacy of medical device innovation in order to further improve patient outcomes and transform health care by reducing costs for all.

Inspiring Good Health Through Cultural Food Traditions

BIOTRONIK is a privately owned, global medical device company with products and services that save and improve the lives of patients suffering from cardiovascular and endovascular diseases. Patient well being is our top priority and has been for more than 50 years.

Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world.

TIKOSYN® (dofetilide) is a prescription medicine. It affects the rhythm of your heart. It is used to treat irregular heartbeats such as atrial fibrillation (AF) and atrial flutter (AFL). It’s only suited for patients who have lots of symptoms. TIKOSYN can be used to help your heart beat normally again and/or to keep it beating that way.

Healthcare is changing. That’s why, as a global leader in medical technology, services, and solutions, we’re collaborating with others to take on the industry’s greatest challenges. is a non-profit initiative developed by physicians from the University of Amsterdam Academic Medical Center, department of Cardiology, in collaboration with a panel of world-renowned experts on Brugada syndrome as an aid to physicians who treat patients with Brugada syndrome and as an aid to patients with Brugada syndrome and their families with the goal to provide free, worldwide accessible and up-to-date information on safe drug use in Brugada syndrome.